MiR-126 in human cancers: Clinical roles and current perspectives

Experimental and Molecular Pathology

Volumn 96, Issue 1, 2014, Pages 98-107

  Ebrahimi, Faeza ^a   Gopalan, Vinod ^a   Smith, Robert Anthony ^a   Lam, Alfred King Yin ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cancer; Carcinoma; MiR 126

Indexed keywords

CANCER; CARCINOMA; MIR-126;

HUMANS; MICRORNAS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893461051     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.12.004     Document Type: Review

References (85)

1. Agostini M., Pucciarelli S., Calore F., Bedin C., Enzo M., Nitti D. miRNAs in colon and rectal cancer: a consensus for their true clinical value. Clin. Chim. Acta 2010, 411:1181-1186.
2. Ahmed F.E., Jeffries C.D., Vos P.W., Flake G., Nuovo G.J., Sinar D.R., Naziri W., Marcuard S.P. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009, 6:281-295.
3. Aslam M.I., Taylor K., Pringle J.H., Jameson J.S. MicroRNAs are novel biomarkers of colorectal cancer. Br. J. Surg. 2009, 96:702-710.
4. Barshack I., Meiri E., Rosenwald S., Lebanony D., Bronfeld M., Aviel-Ronen S., Rosenblatt K., Polak-Charcon S., Leizerman I., Ezagouri M., Zepeniuk M., Shabes N., Cohen L., Tabak S., Cohen D., Bentwich Z., Rosenfeld N. Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int. J. Biochem. Cell Biol. 2010, 42:1355-1362.
5. Bockmeyer C.L., Christgen M., Muller M., Fischer S., Ahrens P., Langer F., Kreipe H., Lehmann U. MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res. Treat. 2011, 130:735-745.
6. Cammarata G., Augugliaro L., Salemi D., Agueli C., La Rosa M., Dagnino L., Civiletto G., Messana F., Marfia A., Bica M.G., Cascio L., Floridia P.M., Mineo A.M., Russo M., Fabbiano F., Santoro A. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am. J. Hematol. 2010, 85:331-339.
7. Chen H., Miao R., Fan J., Han Z., Wu J., Qiu G., Tang H., Peng Z. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin. Exp. Metastasis 2013, 30:651-658.
8. Cho W.C., Chow A.S., Au J.S. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur. J. Cancer 2009, 45:2197-2206.
9. Crawford M., Brawner E., Batte K., Yu L., Hunter M.G., Otterson G.A., Nuovo G., Marsh C.B., Nana-Sinkam S.P. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 2008, 373:607-612.
10. Diaz R., Silva J., Garcia J.M., Lorenzo Y., Garcia V., Pena C., Rodriguez R., Munoz C., Garcia F., Bonilla F., Dominguez G. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008, 47:794-802.
11. Donnem T., Fenton C.G., Lonvik K., Berg T., Eklo K., Andersen S., Stenvold H., Al-Shibli K., Al-Saad S., Bremnes R.M., Busund L.T. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One 2012, 7:e29671.
12. El-Murr N., Abidi Z., Wanherdrick K., Svrcek M., Gaub M.P., Flejou J.F., Hamelin R., Duval A., Lesuffleur T. MiRNA genes constitute new targets for microsatellite instability in colorectal cancer. PLoS One 2012, 7:e31862.
13. Felli N., Felicetti F., Lustri A.M., Errico M.C., Bottero L., Cannistraci A., De Feo A., Petrini M., Pedini F., Biffoni M., Alvino E., Negrini M., Ferracin M., Mattia G., Care A. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One 2013, 8:e56824.
14. Feng R., Chen X., Yu Y., Su L., Yu B., Li J., Cai Q., Yan M., Liu B., Zhu Z. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010, 298:50-63.
15. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., Ivey K.N., Bruneau B.G., Stainier D.Y., Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15:272-284.
16. Fridman E., Dotan Z., Barshack I., David M.B., Dov A., Tabak S., Zion O., Benjamin S., Benjamin H., Kuker H., Avivi C., Rosenblatt K., Polak-Charcon S., Ramon J., Rosenfeld N., Spector Y. Accurate molecular classification of renal tumors using microRNA expression. J. Mol. Diagn. 2010, 12:687-696.
17. Gopalan V., Smith R.A., Nassiri M.R., Yasuda K., Salajegheh A., Kim S.Y., Ho Y.H., Weinstein S., Tang J.C., Lam A.K. GAEC1 and colorectal cancer: a study of the relationships between a novel oncogene and clinicopathologic features. Hum. Pathol. 2010, 41(7):1009-1015.
18. Gopalan V., Pillai S., Ebrahimi F., Salajegheh A., Lam T.C., Le T.K., Langsford N., Ho Y.H., Smith R.E., Lam A.K. Regulation of microRNA-1288 in colorectal cancer: Altered expression and its clinicopathological significance. Mol Carcinog. 2014, [Article in press].
19. Guo C., Sah J.F., Beard L., Willson J.K., Markowitz S.D., Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47:939-946.
20. Hafez M.M., Hassan Z.K., Zekri A.R., Gaber A.A., Al Rejaie S.S., Sayed-Ahmed M.M., Al Shabanah O. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac. J. Cancer Prev. 2012, 13:591-598.
21. Hamada S., Satoh K., Fujibuchi W., Hirota M., Kanno A., Unno J., Masamune A., Kikuta K., Kume K., Shimosegawa T. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol. Cancer Res. 2012, 10:3-10.
22. Han Z.B., Zhong L., Teng M.J., Fan J.W., Tang H.M., Wu J.Y., Chen H.Y., Wang Z.W., Qiu G.Q., Peng Z.H. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol. Oncol. 2012, 6:445-457.
23. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., Warnecke J.M., Sczakiel G. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 2010, 28:655-661.
24. Hansen T.F., Sorensen F.B., Lindebjerg J., Jakobsen A. The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012, 12:83.
25. Hu Y., Correa A.M., Hoque A., Guan B., Ye F., Huang J., Swisher S.G., Wu T.T., Ajani J.A., Xu X.C. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int. J. Cancer 2011, 128:132-143.
26. Huang T.H., Chu T.Y. Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. Oncogene 2013, (Article in press).
27. Ishihara K., Sasaki D., Tsuruda K., Inokuchi N., Nagai K., Hasegawa H., Yanagihara K., Kamihira S. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol. 2012, 36:560-565.
28. Jiao L.R., Frampton A.E., Jacob J., Pellegrino L., Krell J., Giamas G., Tsim N., Vlavianos P., Cohen P., Ahmad R., Keller A., Habib N.A., Stebbing J., Castellano L. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One 2012, 7:e32068.
29. Khella H.W., White N.M., Faragalla H., Gabril M., Boazak M., Dorian D., Khalil B., Antonios H., Bao T.T., Pasic M.D., Honey R.J., Stewart R., Pace K.T., Bjarnason G.A., Jewett M.A., Yousef G.M. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol. 2012, 33:131-140.
30. Kitano M., Rahbari R., Patterson E.E., Xiong Y., Prasad N.B., Wang Y., Zeiger M.A., Kebebew E. Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann. Surg. Oncol. 2011, 18:3443-3452.
31. Ladeiro Y., Couchy G., Balabaud C., Bioulac-Sage P., Pelletier L., Rebouissou S., Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008, 47:1955-1963.
32. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002, 12:735-739.
33. Lam A.K., Ong K., Giv M.J., Ho Y.H. p16 expression in colorectal adenocarcinoma: marker of aggressiveness and morphological types. Pathology 2008, 40(6):580-585.
34. Lam A.K., Ong K., Ho Y.H. Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. Hum. Pathol. 2008, 39(4):599-604.
35. Lam A.K., Ong K., Ho Y.H. hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. Int. J. Colorectal Dis. 2008, 23(6):587-594.
36. Lam A.K., Gopalan V., Nassiri M.R., Kasim K., Dissanayake J., Tang J.C., Smith R.A. Altered JS-2 expression in colorectal cancers and its clinical pathological relevance. Mol Oncol. 2011, 5:475-481.
37. Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., Chen P., Wang Y., Yan M., Qian Z., Neilly M.B., Jin J., Zhang Y., Bohlander S.K., Zhang D.E., Larson R.A., Le Beau M.M., Thirman M.J., Golub T.R., Rowley J.D., Chen J. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15535-15540.
38. Li X., Zhang Y., Zhang Y., Ding J., Wu K., Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010, 59:579-585.
39. Li X.M., Wang A.M., Zhang J., Yi H. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med. Oncol. 2011, 28:1054-1057.
40. Li X., Zhang G., Luo F., Ruan J., Huang D., Feng D., Xiao D., Zeng Z., Chen X., Wu W. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol. Rep. 2012, 28:77-84.
41. Li N., Li X., Huang S., Shen S., Wang X. miR-126 inhibits colon cancer proliferation and invasion through targeting IRS1, SLC7A5 and TOM1 gene. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013, 38:809-817.
42. Li N., Tang A., Huang S., Li Z., Li X., Shen S., Ma J., Wang X. MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol. Cell. Biochem. 2013, 380:107-119.
43. Li Z., Li N., Wu M., Li X., Luo Z., Wang X. Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol. Cell. Biochem. 2013, 381:233-242.
44. Liu B., Peng X.C., Zheng X.L., Wang J., Qin Y.W. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009, 66:169-175.
45. Liu S.G., Qin X.G., Zhao B.S., Qi B., Yao W.J., Wang T.Y., Li H.C., Wu X.N. Differential expression of miRNAs in esophageal cancer tissue. Oncol. Lett. 2013, 5:1639-1642.
46. Meister J., Schmidt M.H. miR-126 and miR-126*: new players in cancer. ScientificWorldJournal 2010, 10:2090-2100.
47. Miko E., Margitai Z., Czimmerer Z., Varkonyi I., Dezso B., Lanyi A., Bacso Z., Scholtz B. miR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5. FEBS Lett. 2011, 585:1191-1196.
48. Miller C.T., Chen G., Gharib T.G., Wang H., Thomas D.G., Misek D.E., Giordano T.J., Yee J., Orringer M.B., Hanash S.M., Beer D.G. Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 2003, 22:7950-7957.
49. Musiyenko A., Bitko V., Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates protein translation and invasiveness of prostate cancer LNCaP cells. J. Mol. Med. (Berl) 2008, 86:313-322.
50. Otsubo T., Akiyama Y., Hashimoto Y., Shimada S., Goto K., Yuasa Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS One 2011, 6:e16617.
51. Png K.J., Halberg N., Yoshida M., Tavazoie S.F. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012, 481:190-194.
52. Powers M.P., Alvarez K., Kim H.J., Monzon F.A. Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping. Diagn. Mol. Pathol. 2011, 20:63-70.
53. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 2009, 112:55-59.
54. Saito Y., Friedman J.M., Chihara Y., Egger G., Chuang J.C., Liang G. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun. 2009, 379:726-731.
55. Salajegheh A., Smith R.A., Kasem K., Gopalan V., Nassiri M.R., William R., Lam A.K. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur. J. Surg. Oncol. 2011, 37:93-99.
56. Salajegheh A., Pakneshan S., Rahman A., Dolan-Evans E., Zhang S., Kwong E., Gopalan V., Lo C.Y., Smith R.A., Lam A.K. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma. Hum. Pathol. 2013, 44:2204-2212.
57. Saleh S., Lam A.K., Ho Y.H. Real-time PCR quantification of human telomerase reverse transcriptase (hTERT) in colorectal cancer. Pathology 2008, 40(1):25-30.
58. Sasahira T., Kurihara M., Bhawal U.K., Ueda N., Shimomoto T., Yamamoto K., Kirita T., Kuniyasu H. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br. J. Cancer 2012, 107:700-706.
59. Schmitt J., Backes C., Nourkami-Tutdibi N., Leidinger P., Deutscher S., Beier M., Gessler M., Graf N., Lenhof H.P., Keller A., Meese E. Treatment-independent miRNA signature in blood of Wilms tumor patients. BMC Genomics 2012, 13:379.
60. Shen W.F., Hu Y.L., Uttarwar L., Passegue E., Largman C. MicroRNA-126 regulates HOXA9 by binding to the homeobox. Mol. Cell. Biol. 2008, 28:4609-4619.
61. Slaby O., Svoboda M., Michalek J., Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol. Cancer 2009, 8:102.
62. Sun Y., Bai Y., Zhang F., Wang Y., Guo Y., Guo L. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem. Biophys. Res. Commun. 2010, 391:1483-1489.
63. Sun Y.Q., Zhang F., Bai Y.F., Guo L.L. miR-126 modulates the expression of epidermal growth factor-like domain 7 in human umbilical vein endothelial cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:767-770.
64. Tahiri A., Leivonen S.K., Luders T., Steinfeld I., Ragle Aure M., Geisler J., Makela R., Nord S., Riis M.L., Yakhini Z., Kleivi Sahlberg K., Borresen-Dale A.L., Perala M., Bukholm I.R., Kristensen V.N. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 2013, 35:76-85.
65. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
66. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., Richardson J.A., Bassel-Duby R., Olson E.N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
67. Wang X., Tang S., Le S.Y., Lu R., Rader J.S., Meyers C., Zheng Z.M. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3:e2557.
68. Wang F., Zheng Z., Guo J., Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 2010, 119:586-593.
69. Wang X.Y., Wu M.H., Liu F., Li Y., Li N., Li G.Y., Shen S.R. Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol. Cell. Biochem. 2010, 345:283-290.
70. Wang X.C., Du L.Q., Tian L.L., Wu H.L., Jiang X.Y., Zhang H., Li D.G., Wang Y.Y., Wu H.Y., She Y., Liu Q.F., Fan F.Y., Meng A.M. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 2011, 72:92-99.
71. Wang Y., Shi J., Wu Y., Xu W., Wang Q., Zhang J., Jiang M., Gu G. Use of Luminex xMAP bead-based suspension array for detecting microRNA in NSCLC tissues and its clinical application. Tumori 2012, 98:792-799.
72. Wang J., Chen X., Li P., Su L., Yu B., Cai Q., Li J., Yu Y., Liu B., Zhu Z. CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126. Chem. Biol. Interact. 2013, 206:230-238.
73. Watahiki A., Wang Y., Morris J., Dennis K., O'Dwyer H.M., Gleave M., Gout P.W., Wang Y. MicroRNAs associated with metastatic prostate cancer. PLoS One 2011, 6:e24950.
74. Weekes J., Ho Y.H., Sebesan S., Ong K., Lam A.K. Irinotecan and colorectal cancer: the role of p53, VEGF-C and alpha-B-crystallin expression. Int. J. Colorectal Dis. 2010, 25:907.
75. White N.M., Khella H.W., Grigull J., Adzovic S., Youssef Y.M., Honey R.J., Stewart R., Pace K.T., Bjarnason G.A., Jewett M.A., Evans A.J., Gabril M., Yousef G.M. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br. J. Cancer 2011, 105:1741-1749.
76. Xu J.Q., Liu P., Si M.J., Ding X.Y. MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour Biol. 2013, 34:3871-3877.
77. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
78. Yang J., Lan H., Huang X., Liu B., Tong Y. MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One 2012, 7:e42978.
79. Youssef Y.M., White N.M., Grigull J., Krizova A., Samy C., Mejia-Guerrero S., Evans A., Yousef G.M. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur. Urol. 2011, 59:721-730.
80. Yu X.M., Lo C.Y., Chan W.F., Lam K.Y., Leung P., Luk J.M. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin. Cancer Res. 2005, 11:8063-8069.
81. Yu X.M., Lo C.Y., Lam A.K., Lang B.H., Leung P., Luk J.M. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 2008, 144:934-940. (discussion 940-1).
82. Yu T., Wang X.Y., Gong R.G., Li A., Yang S., Cao Y.T., Wen Y.M., Wang C.M., Yi X.Z. The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J. Exp. Clin. Cancer Res. 2009, 28:64.
83. Zhang J., Du Y.Y., Lin Y.F., Chen Y.T., Yang L., Wang H.J., Ma D. The cell growth suppressor, mir-126, targets IRS-1. Biochem. Biophys. Res. Commun. 2008, 377:136-140.
84. Zhu N., Zhang D., Xie H., Zhou Z., Chen H., Hu T., Bai Y., Shen Y., Yuan W., Jing Q., Qin Y. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol. Cell. Biochem. 2011, 351:157-164.
85. Zhu X., Li H., Long L., Hui L., Chen H., Wang X., Shen H., Xu W. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:519-526.